首页> 外国专利> PROSTATIC LIQUID BIOPSY FOR THE DETECTION OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA

PROSTATIC LIQUID BIOPSY FOR THE DETECTION OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA

机译:前列腺液活检检测前列腺癌和良性前列腺增生症

摘要

Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into the urethra are then collected non-invasively, such as through urine or semen samples. Such collection is further strategically calculated relative the administration of the agent so as to maximize the sample collection of the target cells of interest. The exfoliated prostatic epithelial cells are subsequently utilized for purposes such as detecting prostate cancer, predicting/measuring prostate tumor susceptibility to drug regimes, active surveillance of patients whose prostate biopsy results are negative, but continue to exhibit symptoms consistent with prostate cancer, and identifying false positive results associated with biomarker assays.
机译:公开了诱导靶前列腺细胞从前列腺器官移出,收集所述细胞并随后检查细胞群体的方法。这样的方法包括给予促进靶细胞从前列腺内移出然后再迁移到尿道中的试剂的施用。示例性的试剂包括5种α-还原酶抑制剂。然后无创地收集诱导进入尿道的细胞,例如通过尿液或精液样品。相对于试剂的施用进一步策略性地计算这样的收集,以便最大化感兴趣的靶细胞的样品收集。剥落的前列腺上皮细胞随后用于以下目的,例如检测前列腺癌,预测/测量前列腺肿瘤对药物治疗的敏感性,对前列腺活检结果为阴性但继续表现出与前列腺癌一致的症状的患者进行主动监视,以及识别假与生物标志物测定有关的阳性结果。

著录项

  • 公开/公告号EP3426310A1

    专利类型

  • 公开/公告日2019-01-16

    原文格式PDF

  • 申请/专利权人 WAVESENSE INC;

    申请/专利号EP20170763856

  • 发明设计人 FEISTEL CHRISTOPHER;

    申请日2017-03-07

  • 分类号A61K51/10;C07K16/40;

  • 国家 EP

  • 入库时间 2022-08-21 12:27:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号